Aromatase inhibitors: development and current perspectives (Record no. 17348)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | a |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20220829092830.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 220829b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 17634 |
| Author | Sayyad, Nusrat B. |
| 245 ## - TITLE STATEMENT | |
| Title | Aromatase inhibitors: development and current perspectives |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol.56(2), Apr-June |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Karnataka |
| Name of publisher, distributor, etc. | Association of Pharmaceutical Teachers of India (APTI) |
| Year | 2022 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 311-320p. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Aim: Breast cancer is one of the most common cancers among women, consistently elevated estrogen level in the blood associated with persistently in breast cancer found in many studies. The mechanisms of carcinogenesis whereby cancer is associated involved in the conversion of androgen to estrogen in the presence of enzyme aromatase. Materials and Methods: Aromatase is a (CYP19), a cytochrome P450, which is the enzyme that synthesizes estrogen. Aromatase which is expressed in higher concentration in breast play a pivotal role in the origin and progression of breast cancer. In situ inhibition of aromatase enzyme accomplished by the prevention of aromatase expression in breast cancer. Results: The success of aromatase inhibition could result in the suppression and progression of breast cancer. One of the ways to reduce the incidence of breast cancer by inhibiting estrogen biosynthesis in breast tissue. Aromatase inhibitor therapy is considered for second-line treatment in patients who fail anti-estrogen therapy. Conclusion: Several potent and selective aromatase inhibitors have been developed and used to treat breast cancer. Some of them have passed clinical trial phase II. Development in the field has encouraged us to review work on the Aromatase inhibitor. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4639 |
| Topical term or geographic name entry element | PHARMACEUTICS |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 17635 |
| Co-Author | Sabale, Prafulla M. |
| 773 0# - HOST ITEM ENTRY | |
| Place, publisher, and date of publication | Bengluru Association of Pharmaceutical Teachers of India (APTI) |
| International Standard Serial Number | 0019-5464 |
| Title | Indian journal of pharmaceutical education and research |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| URL | https://www.ijper.org/sites/default/files/IndJPhaEdRes-56-2-311.pdf |
| Link text | Click here |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Permanent Location | Current Location | Shelving location | Date acquired | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| School of Pharmacy | School of Pharmacy | Archieval Section | 2022-08-29 | 2022-1415 | 2022-08-29 | 2022-08-29 | Articles Abstract Database |